Bilastine - CAS# 202189-78-4 enzyl)-N2 N2-dimethyl-N1-(pyridin-2-yl)ethane-1 2-diamine hydrochloride 7aH-cyclopenta[c]pyran-4-carboxylic acid

7aH-cyclopenta[c]pyran-4-carboxylic acid

InChi: InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5

phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM)

The inhibition of the ROCK pathway through GSK 269962 appeared to have no effect on either HR(heart rate)

Chemical Name: 2-(7-Methoxy-4-methyl-2-quinazolinyl)guanidine

Bilastine - CAS# 202189-78-4 enzyl)-N2 N2-dimethyl-N1-(pyridin-2-yl)ethane-1 2-diamine hydrochloride 7aH-cyclopenta[c]pyran-4-carboxylic acidBilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives). It exerts its effect as a selective histamine H1 receptor antagonist, and has a potency similar to cetirizine and is superior to fexofenadine. It was developed in Spain by FAES Farma. Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but